Dexcom Inc (NASDAQ:DXCM) shares traded -2.35% lower at $115.30 on Wall Street last session.
DXCM stock price is now -11.89% away from the 50-day moving average and -0.17% away from the 200-day moving average. The market capitalization of the company currently stands at $45.85B.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target of $130, Redburn Atlantic recently initiated with Neutral rating for Dexcom Inc (NASDAQ: DXCM). On March 12, 2024, RBC Capital Mkts recently initiated its ‘Outperform’ rating on the stock quoting a target price of $165, while ‘Morgan Stanley’ rates the stock as ‘Equal-Weight’
In other news, Brown Michael Jon, EVP Chief Legal Officer sold 652 shares of the company’s stock on May 31 ’24. The stock was sold for $77,744 at an average price of $119.24. Upon completion of the transaction, the EVP Chief Legal Officer now directly owns 67,560 shares in the company, valued at $7.79 million. An SEC document containing details of the transaction can be found on the SEC’s website. On May 15 ’24, EVP Strategy and Corporate Dev Dolan Matthew Vincent sold 2,423 shares of the business’s stock. A total of $306,703 was realized by selling the stock at an average price of $126.58. This leaves the insider owning 40,075 shares of the company worth $4.62 million. A total of 1.59% of the company’s stock is owned by insiders.
During the past 12 months, Dexcom Inc has had a low of $74.75 and a high of $142.00. As of last week, the company has a debt-to-equity ratio of 1.15, a current ratio of 2.90, and a quick ratio of 2.53. According to the stock market information, the enterprise value for the company is $45530140672, which is based on a 74.44 price-to-earnings ratio, a 4.68 price-to-earnings-growth ratio, and a beta of 1.17. The fifty day moving average price for DXCM is $130.3722 and a two-hundred day moving average price translates $115.5469 for the stock.
The latest earnings results from Dexcom Inc (NASDAQ: DXCM) was released for 2024-03-31. The net profit margin was 16.82% and return on equity was 28.54% for DXCM. The company reported revenue of $921.0 million for the quarter, compared to $741.5 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 24.21 percent.
